Resumen
Personalized implants with antimicrobial activity to prevent and treat bone infections. The current treatments of surgical location infections caused by fungi or bacteria with antibiotics and antifungals, are usually based on the prolonged intravenous administration or the use of polymethylecrilate cements after removing the prosthesis and cleaning the surrounding tissues, which makes another surgical process necessary. However, an administration system that avoids high body exposure to antimicrobial and that the patient should undergo new surgery would be more desirable. The present invention describes 3D printed implants with biocompatible and biodegradable polymers that comprise drugs with an immediate - sustained release with a reduced hemolytic profile, which are easily adherible to prostheses, they have a good in vitro efficacy profile against different mushroom strains and bacteria and can be sterilized by the action of UV light due to their fine thickness. (Machine-translation by Google Translate, not legally binding)
Reivindicaciones
1. Parenteral implant with an immediate-controlled drug release, consisting of biocompatible and biodegradable materials with a spiderweb shape of a millimetric thickness and contains anti-infective active ingredients. 2. Implant, according to claim 1, where the biocompatible materials of the implant are polyvinyl alcohol, polycaprolactone, polyethylene glycol or a mixture thereof. 3. Implant, according to claim 1, where the spiderweb consists of a central circle with multiple radial filaments with several central supports. 4. Implant, according to claim 3, where the radial filaments can be joint or separated with a gap. 5. Implant, according to claim 4, where the gaps are at least of 100 µm. 6. Implants, according to previous claims, where filaments have the following dimensions ranging from 10-30 mm length and 5-10 mm width. 7. Implants, according to previous claims, where the active ingredient is an antibiotic. 8. Implant, according to claim 5, where the antibiotic is vancomycin. 9. Implant, according to claims 1 to 6, where the active ingredient is an antifungal. 10. Implant, according to claim 9, where the antifungal is amphotericin B. 11. Implant, according to claims 1 to 6, characterized for containing both antibiotics and antifungals. 12. Implant, according to claim 11, where the antibiotic is vancomycin, and the antifungal is amphotericin. 13. Method of obtaining the claimed implant comprising: - Design the shape of the implant. - Print the implant designed using a 3D printing technique with biocompatible and biodegradable materials. - Load the printed implant with anti-infective active ingredients through passive diffusion. 14. Method, according to claim 13, where the implant is designed based on the dimensions of the acetabular cup on which the implant means to be fitted using a CAD (Computer Aided Design) program. 15. Method, according to claim 13, where the 3D printing implant is made from a biocompatible or biodegradable filament using FDM (Fused Deposition Modeling). 16. Method, according to claim 13, where the 3D printing implant is made from a biocompatible or biodegradable filament using a direct powder extrusion method. 17. Method, according to claim 13, where the biocompatible materials that constitute the implant are polyvinyl alcohol, polycaprolactone, polyethylene glycol or a mixture of them. 18. Method, according to claim 13, where the active anti-infective ingredients are antibiotics, antifungals or a mixture of them. 19. Method, according to claim 18, where the anti-infective active ingredients are vancomycin, amphotericin B, or a mixture of them. 20. Method, according to claims 13 to 19, where, optionally, the implant obtained is sterilized by UV light. 21. Use of claimed implants can be for the prevention and treatment of infections derived from arthroplasties or heart valvopathies. 22. Use of claimed implants, according to claim 20, where the implants is previously wetted before administration directly during the surgical procedure.
